Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
This study is ongoing, but not recruiting participants.
Study NCT00020761 Information provided by National Cancer Institute (NCI)
First Received: July 11, 2001 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Esophageal Cancer
Gastric Cancer
Additional conditions recognized in this trial
Adenocarcinoma
Esophageal Diseases
Esophageal Neoplasms
Stomach Neoplasms
More general conditions related to this trial
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Stomach Diseases
Interventions listed in this trial
irinotecan hydrochloride
paclitaxel
Additional drug interventions recognized in this trial
Camptothecin
Irinotecan
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
